Tacrolimus decreases insulin sensitivity without reducing fasting insulin concentration: A 2-year follow-up study in kidney transplant recipients

Renal Failure

Volumn 37, Issue 4, 2015, Pages 601-606

  Chen, Qing Jie ^a   Li, Jing ^a,b   Zuo, Shan Ru ^a   Zhang, Ya Ping ^a   Jia, Su Jie ^a   Yuan, Hong ^a   Liu, Shi Kun ^a   Cheng, Ke ^a   Ming, Ying Zi ^a   Zuo, Xiao Cong ^a   Luo, Ai Jing ^c   Xie, Wen Zhao ^a   Cai, Jing Jing ^a   Yang, Meng ^a   Wang, Jiang Lin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HUNAN CHILDREN'S HOSPITAL   (China)

^c Key Laboratory of Medical Information Research in Hunan Higher Education   (China)

Author keywords

IRS 1; IRS 2; PTDM; SNP; TAC

Indexed keywords

ARGININE; ASPARTIC ACID; C PEPTIDE; GLYCINE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; ALLELE; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; FOLLOW UP; GENE FREQUENCY; GENOTYPE; GRAFT RECIPIENT; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEW ONSET DIABETED AFTER TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CHEMICALLY INDUCED; COHORT ANALYSIS; DIABETES MELLITUS; GENETICS; INSULIN RESISTANCE; POSTOPERATIVE COMPLICATIONS; RISK FACTOR; TIME;

ADULT; COHORT STUDIES; DIABETES MELLITUS; FASTING; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INSULIN RESISTANCE; KIDNEY TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TACROLIMUS; TIME FACTORS;

EID: 84930329429     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2015.1007833     Document Type: Article

References (22)

1. Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant. 2005;19:291-298.
2. Moore R, Boucher A, Carter J, et al. Diabetes mellitus in transplantation: 2002 consensus guidelines. Transplant Proc. 2003;35:1265-1270.
3. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178-185.
4. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000;11:1735-1743.
5. Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of posttransplant diabetes. Kidney Int. 2002;62:1440-1446.
6. Marin M, Renoult E, Bondor CI, Kessler M. Factors influencing the onset of diabetes mellitus after kidney transplantation: A single French center experience. Transplant Proc. 2005;37:1851-1856.
7. Roozbeh J, Mehdizadeh AR, Razmkon A, Malek-Hosseini SA. Incidence of posttransplantation diabetes mellitus in kidney transplantation: A single-center experience. Transplant Proc. 2005; 37:3095-3097.
8. Seifi S, Rahbar M, Lessan-Pezeshki M, et al. Posttransplant diabetes mellitus: Incidence and risk factors. Transplant Proc. 2009;41:2811-2813.
9. Hagen M, Hjelmesaeth J, Jenssen T, Morkrid L, Hartmann A. A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients. Nephrol Dial Transplant. 2003;18:2154-2159.
10. Boots JM, van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus: The effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol. 2002;13:221-227.
11. Hur KY, Kim MS, Kim YS, et al. Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care. 2007;30:609-615.
12. Lohmann T, List C, Lamesch P, et al. Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunsuppressive therapy by FK506/tacrolimus. Exp Clin Endocrinol Diabetes. 2000; 108:347-352.
13. van Hooff JP, Christiaans MH, van Duijnhoven EM. Evaluating mechanisms of post-Transplant diabetes mellitus. Nephrol Dial Transplant. 2004;19(Suppl. 6):vi8-vi12.
14. Kido Y, Burks DJ, Withers D, et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest. 2000;105:199-205.
15. Zuo XC, Ng CM, Barrett JS, et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: A population pharmacokinetic analysis. Pharmacogenet Genomics. 2013;23:251-261.
16. Chan S-H. Gly1057Asp polymorphism of insulin receptor substrate-2 is associated with coronary artery disease in the Taiwanese population Chan et al. J Biomed Sci. 2012;19:100-108.
17. Baba T. Polycystic ovary syndrome is associated with genetic polymorphism in the insulin signaling gene IRS-1 but not ENPP1 in a Japanese population. Life Sci. 2007;81:850-854.
18. Sui W, Zou H, Zou G, et al. Clinical study of the risk factors of insulin resistance and metabolic syndrome after kidney transplantation. Transpl Immunol. 2008;20:95-98.
19. Withers DJ, Gutierrez JS, Towery H, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature. 1998;391: 900-904.
20. Almind K, Frederiksen SK, Bernal D, et al. Search for variants of the gene-promoter and the potential phosphotyrosine encoding sequence of the insulin receptor substrate-2 gene: Evaluation of their relation with alterations in insulin secretion and insulin sensitivity. Diabetologia. 1999;42:1244-1249.
21. Stefan N, Fritsche A, Machicao F, Tschritter O, Haring HU, Stumvoll M. The Gly1057Asp polymorphism in IRS-2 interacts with obesity to affect beta cell function. Diabetologia. 2004;47:759-761.
22. Jellema A, Zeegers MP, Feskens EJ, Dagnelie PC, Mensink RP. Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: A meta-Analysis of 27 studies. Diabetologia. 2003;46:990-995.